Phase II Study of S-877489 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long term Extension Study-

Phase II Study of S-877489 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long Term Extension Study-

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222082

Enrollment

Registered

2013-05-14

Start date

2013-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/Hyperactivity Disorder

Interventions

investigational material(s) Generic name etc : Lisdexamfetamine Mesilate INN of investigational material : Lisdexamfetamine Mesilate Therapeutic category code : 117 Psychotropic agents Dosage and Admi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who hope to continue treatment with S-877489 after the preceding study. etc.

Exclusion criteria

Exclusion criteria: Patients who have complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease. etc.

Design outcomes

Primary

Measure	Time frame
safety The presence or absence of adverse events/reactions and their incidence, etc.	—

Secondary

Measure	Time frame
efficacy ADHD RS-IV, etc.	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

Takeda Pharmaceutical Company Limited

smb.Japanclinicalstudydisclosure@takeda.com+81-6-6204-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026